Structure-Based Design of Selective Noncovalent CDK12 Inhibitors.
Johannes, J.W., Denz, C.R., Su, N., Wu, A., Impastato, A.C., Mlynarski, S., Varnes, J.G., Prince, D.B., Cidado, J., Gao, N., Haddrick, M., Jones, N.H., Li, S., Li, X., Liu, Y., Nguyen, T.B., O'Connell, N., Rivers, E., Robbins, D.W., Tomlinson, R., Yao, T., Zhu, X., Ferguson, A.D., Lamb, M.L., Manchester, J.I., Guichard, S.(2018) ChemMedChem 13: 231-235
- PubMed: 29266803 
- DOI: https://doi.org/10.1002/cmdc.201700695
- Primary Citation of Related Structures:  
6B3E - PubMed Abstract: 
Cyclin-dependent kinase (CDK) 12 knockdown via siRNA decreases the transcription of DNA-damage-response genes and sensitizes BRCA wild-type cells to poly(ADP-ribose) polymerase (PARP) inhibition. To recapitulate this effect with a small molecule, we sought a potent, selective CDK12 inhibitor ...